Rigel Pharmaceuticals (RIGL) Competitors

Celldex Therapeutics (NASDAQ:CLDX) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, community ranking, media sentiment, analyst recommendations, risk, dividends and valuation.

Do analysts prefer CLDX or RIGL?

Celldex Therapeutics presently has a consensus target price of $53.90, suggesting a potential upside of 156.30%. Rigel Pharmaceuticals has a consensus target price of $36.40, suggesting a potential upside of 68.83%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Celldex Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	0 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.90
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.40

Is CLDX or RIGL more profitable?

Rigel Pharmaceuticals has a net margin of 2.46% compared to Celldex Therapeutics' net margin of -1,544.32%. Rigel Pharmaceuticals' return on equity of -14.80% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	-1,544.32%	-19.75%	-18.86%
Rigel Pharmaceuticals	2.46%	-14.80%	3.03%

Which has more risk & volatility, CLDX or RIGL?

Celldex Therapeutics has a beta of 1.33, indicating that its stock price is 33% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the S&P 500.

Does the MarketBeat Community favor CLDX or RIGL?

Celldex Therapeutics received 160 more outperform votes than Rigel Pharmaceuticals when rated by MarketBeat users. Likewise, 75.27% of users gave Celldex Therapeutics an outperform vote while only 68.88% of users gave Rigel Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Celldex Therapeutics	Outperform Votes 627 75.27%	Underperform Votes 206 24.73%
Rigel Pharmaceuticals	Outperform Votes 467 68.88%	Underperform Votes 211 31.12%

Do insiders & institutionals have more ownership in CLDX or RIGL?

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Which has stronger valuation & earnings, CLDX or RIGL?

Rigel Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$7.56M	184.69	-$141.43M	-$2.70	-7.79
Rigel Pharmaceuticals	$203.08M	1.90	-$25.09M	$2.07	10.42

Does the media prefer CLDX or RIGL?

In the previous week, Celldex Therapeutics had 6 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 14 mentions for Celldex Therapeutics and 8 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.40 beat Celldex Therapeutics' score of 1.16 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celldex Therapeutics	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rigel Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Rigel Pharmaceuticals beats Celldex Therapeutics on 10 of the 19 factors compared between the two stocks.